Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE38.2600
- TODAY'S CHANGE (%)-0.0300 (-0.0783%)
- Bid / Lots38.2000/ 2
- Ask / Lots38.3200/ 1
- Open / Previous Close38.4200 / 38.2900
- Day Range
- 52 Week Range
- Volume19,840
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 614 | 38.405 |
| 09:34 ET | 2400 | 38.63 |
| 09:36 ET | 200 | 38.95 |
| 09:38 ET | 100 | 38.775 |
| 09:39 ET | 300 | 38.705 |
| 09:41 ET | 100 | 38.74 |
| 09:43 ET | 100 | 38.69 |
| 09:45 ET | 300 | 38.5 |
| 09:50 ET | 658 | 38.62 |
| 09:52 ET | 400 | 38.63 |
| 09:57 ET | 100 | 38.5 |
| 10:01 ET | 100 | 38.38 |
| 10:06 ET | 200 | 38.615 |
| 10:08 ET | 100 | 38.425 |
| 10:10 ET | 300 | 38.4 |
| 10:15 ET | 100 | 38.435 |
| 10:17 ET | 100 | 38.625 |
| 10:21 ET | 600 | 38.605 |
| 10:24 ET | 200 | 38.69 |
| 10:30 ET | 809 | 38.6 |
| 10:32 ET | 547 | 38.535 |
| 10:35 ET | 246 | 38.39 |
| 10:37 ET | 100 | 38.405 |
| 10:39 ET | 636 | 38.535 |
| 10:42 ET | 300 | 38.31 |
| 10:44 ET | 300 | 38.26 |
| 10:46 ET | 500 | 38.36 |
| 10:48 ET | 130 | 38.35 |
| 10:51 ET | 100 | 38.295 |
| 10:55 ET | 100 | 38.255 |
| 10:57 ET | 200 | 38.26 |
| 11:00 ET | 200 | 38.245 |
| 11:02 ET | 429 | 38.26 |
May 28, 2024
May 10, 2024
DJ Xenon Pharmaceuticals Is Maintained at Buy by Needham, from 6:12PM ET on Friday May 10, 2024 by Dow Jones
6:12PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Buy by Citigroup, from 5:48PM ET on Friday May 10, 2024 by Dow Jones
5:48PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush, from 9:30AM ET on Friday May 10, 2024 by Dow Jones
9:30AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 2.9B | -14.1x | --- |
Biohaven Ltd | 2.9B | -5.2x | --- |
Dyne Therapeutics Inc | 3.0B | -7.9x | --- |
SpringWorks Therapeutics Inc | 3.0B | -8.1x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Apogee Therapeutics Inc | 2.6B | -22.3x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.23 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -14.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
